Colorectal Cancer Panel
- Colorectal cancer starts when cells in the colon or rectum grow out of control and crowd out normal cells. It usually starts in the inner lining of the colon or rectum and can travel from there. Colorectal cancer is the third most common cancer diagnosed in both men and women in the US. The lifetime risk of developing colorectal cancer is about 1 in 21 for men and 1 in 23 for women (1). About 5 to 10 percent of all colorectal cancers are caused by a heritable mutation. The two major subtypes of hereditary colon cancer are called familial adenomatous polyposis and Lynch syndrome (2). In addition to the syndromes, up to one third of colon cancers exhibit increased familial risk that is likely related to inheritance (3). Several genes associated with CRC risk have been identified and are known to cause a predisposition to CRC. Genetic testing is recommended to better understand individual cancer risk as well as family risks (4).
- Genes (24): APC, AXIN2, BMPR1A, BUB1B, CDH1, CDKN2A, CHEK2, CTNNB1, EPCAM, EXO1, FLCN, KIT, MLH1, MLH3, MSH2, MSH6, MUTYH, NF1, PMS1, PMS2, PTEN, SMAD4, STK11, and TP53
Test Code: 2025
• Molecular confirmation of a clinical diagnosis in symptomatic patients.
• Assessment for at-risk family members
Test Info Sheet: Colorectal Cancer Panel
Requisition: Contact ApolloGen Diagnostic Laboratory
- Turn-Around Time: 4 Weeks
Preferred Specimen: 3-5 mL Whole Blood – Lavender Top Tube
Other Specimens: See details here
- CPT Codes: 81201×1, 81272×1, 81292×1, 81295×1, 81298×1, 81317×1, 81321×1, 81403×1, 81404×1, 81405×2, 81406×3, 81408×1, 81479×9
Pricing: Please contact us at (949) 916-8886 or firstname.lastname@example.org
- Methodology: Next-Generation Sequencing (NGS)
Colon Cancer Panel
iGene Cancer Panel